TTAC-0001

DRUG2 trials

Sponsors

PharmAbcine

Conditions

Recurrent Glioblastoma

Phase 2

Trial to Evaluate the Safety of TTAC-0001(Tanibirumab) in Recurrent Glioblastoma

CompletedNCT03033524

PharmAbcineRecurrent Glioblastoma

Start: 2016-02-04End: 2017-06-02Updated: 2021-01-27

TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab

TerminatedNCT03856099

PharmAbcineRecurrent Glioblastoma

Start: 2019-11-13End: 2022-07-15Updated: 2022-08-18

Related Papers

ACTR-75. A MULTICENTER, 3-ARM, OPEN-LABEL, PHASE IIA CLINICAL TRIAL TO EVALUATE SAFETY AND EFFICACY OF TANIBIRUMAB (VEGFR2 MAB), IN PATIENTS WITH RECURRENT GBM ASSESSED WITH K-TRANS AND INITIAL AREA UNDER THE GADOLINIUM CONCENTRATION-TIME CURVE (IAUGC)

Neuro-Oncology2017-11-019 citations

A multicenter, 3-arm, open-label, phase IIa clinical trial to evaluate the safety and efficacy of tanibirumab (VEGFR2 mAb), in patients with recurrent glioblastoma (GBM).

Journal of Clinical Oncology2017-05-205 citations